Regions Financial Corp’s Acadia Pharmaceuticals ACAD Stock Holding History

Regions Financial Corp’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-22	Closed	-$1K	–	830
2019 Q1	$1K	Hold	22	–	–	﹤0.01%	1825
2018 Q4	$0	Hold	22	–	–	﹤0.01%	1892
2018 Q3	$0	Hold	22	–	–	﹤0.01%	1957
2018 Q2	$0	Buy	+22	New	+$392	﹤0.01%	2068

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Regions Financial Corp's ACAD Position: Q2 2019 in Review

Regions Financial Corp sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 22 shares — an estimated $1K sold.

Regions Financial Corp first reported a position in ACAD in Q2 2018 and held it in 4 quarters. The position peaked at $1K in Q1 2019. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

Regions Financial Corp reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Regions Financial Corp sold 22 Acadia Pharmaceuticals shares in Q2 2019, an estimated $1K.
Regions Financial Corp first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 4 quarters.
Regions Financial Corp's Acadia Pharmaceuticals position peaked at $1K in Q1 2019.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on Regions Financial Corp's 13F filing for Q2 2019, filed 19 Jul 2019.